Preexposure Rabies Vaccination
1994; Oxford University Press; Volume: 1; Issue: 1 Linguagem: Inglês
10.1111/j.1708-8305.1994.tb00556.x
ISSN1708-8305
Autores Tópico(s)Viral Infections and Outbreaks Research
ResumoPreexposure rabies vaccination consists of the provision of protective antibodies to individuals who are potentially at risk of being infected with rabies.' This is done by giving three primary injections of a tissue culture rabies vaccine one each on day 0,7, and 28 (a few days variation in timing is acceptable). The vaccine is administered either as a full dose (usually 1 mL) intramuscularly or 0.1 mL intradermally. Intramuscular injections are given into the deltoid region (or lateral thigh muscle in small children).' Human diploid cell rabies vaccine (HDCV) and rhesus monkey diploid fetal lung cell vaccines (Michigan State Laboratory) are currently the products available in North America. Other tissue culture vaccines of proven quality are marketed abroad, and several are now being considered for approval in America. They are Purified Vero Cell Rabies Vaccine (PVRV) made by the Merieux Co in France, Purified Duck Embryo Vaccine (PDEV) made by the Swiss Serum and Vaccine Institute (not t o be confused with the poorly immunogenic old Duck Embryo Vaccines), and Purified Chick Embryo Rabies Vaccine (PCEC) made by Behring in Germany and the Chemo-Sero Institute in Japan. East European and Chinese firms manufacture tissue culture vaccines grown in baby hamster cells, but there is little independent literature in peer review journals attesting to their consistent quality control and immunogenicity. Many countries still manufacture and use central nervous tissue-derived rabies vaccines such as Semple and suckling mouse brain products. Most of these are of uncertain immunogenicity and carry a risk of severe adverse neurologic reaction^.^,^ Brain tissue-derived rabies vaccines are not to be used for preexposure vaccination due to an unacceptably poor risubenefit ratio.',
Referência(s)